Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

RADNOR, Pa., June  24, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a  webinar  featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which will take place on  Tuesday, June 30, 2020 from 8am – 10.30am Eastern Time.

Marinus Pharmaceuticals to Host Pipeline Update Webinar

RADNOR, Pa., June  22, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum.

Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

RADNOR, Pa., June  15, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary.

Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary

RADNOR, Pa., June  02, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per share, including the exercise in full by the underwriters of their option to purchase up to 2,400,000 additional shares of common stock. The offering raised gross proceeds of approximately $46 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., May  28, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $2.50 per share. The gross proceeds of the offering to the Company are expected to be approximately $40,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about June 2, 2020, subject to the satisfaction of customary closing conditions. Cowen and Cantor Fitzgerald & Co. are acting as lead book-running managers for the offering. SunTrust Robinson Humphrey is acting as a bookrunner for the offering. Oppenheimer & Co. Inc. is acting as lead manager for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering. Marinus intends to use the net proceeds of the offering to fund the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-221243) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 1, 2017. A preliminary prospectus supplement relating to the offering was filed with the SEC on May 28, 2020 and is available on the SEC’s website at http://www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SEC’s website. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about the Company and the offering. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at  PostSaleManualRequests@broadridge.com , or Cantor Fitzgerald & Co., 499 Park Avenue, 6th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com.   This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  About Marinus Pharmaceuticals

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

RADNOR, Pa., May  28, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Marinus. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Marinus intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offered in the public offering.

Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2020 Results - Earnings Call Transcript

Board includes 6 globally recognized seizure disorder experts Board includes 6 globally recognized seizure disorder experts

Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board

RADNOR, Pa., April  27, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to two new employees. A majority of the independent members of the Board of Directors of Marinus granted the new employees non-qualified stock options to purchase an aggregate of 45,500 shares of its common stock as inducement awards material to each employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Marinus Pharmaceuticals  - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics

Biohaven Pharmaceutical Hld

CymaBay Therapeutics

PTC Therapeutics

Solid Biosciences

Telesis Bio Inc

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

7 Disruptive Biotech Stocks to Buy for 2025

RADNOR, Pa., March  23, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company”, “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Marinus granted the new employees non-qualified stock options to purchase an aggregate of 228,500 shares of its common stock and an aggregate of 21,000 shares of restricted common stock, as inducement awards material to each employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

MARINUS PHARMACEUTICALS   ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

Implied Volatility Surging for Marinus (MRNS) Stock Options

RADNOR, Pa., March  19, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced the appointment of Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications, reporting to Scott Braunstein, M.D., Chief Executive Officer of Marinus. In this role, Ms. Damouni Ellis will lead strategic investor relations and communications programs, and will work closely with investors, employees, advocacy groups, patient organizations and the media.

Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications

Top-line data on-track for Q3 2020 Top-line data on-track for Q3 2020

Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

RADNOR, Pa., Feb.  14, 2020  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 60,000 shares of its common stock to new employees, with a grant date of February 5, 2020.

Marinus  Pharmaceuticals  Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020

Marinus Provides Business Outlook for 2020

RADNOR, Pa., Jan.  07, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today announced that Dr. Scott Braunstein, Chief Executive Officer, will present a corporate overview at the 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 11:00am Pacific Time. The conference will take place at the Westin St. Francis Hotel in San Francisco, California.

Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.

Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%

RADNOR, Pa., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 121,000 shares of its common stock to new employees, with a grant date of December 11, 2019.

Marinus Pharmaceuticals  Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 32,200,000 shares of common stock at a public offering price of $1.25 per share, including the exercise in full by the underwriters of their option to purchase up to 4,200,000 additional shares of common stock. The offering included participation from new and existing investors, and together with the concurrent private placement raised gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions, placement agent fees and estimated offering expenses payable by the Company.

Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Dec.  12, 2019  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced today that Elan Ezickson, has joined the Company’s Board of Directors.  Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic leadership roles.

Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

RADNOR, Pa., Dec.  11, 2019  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per share. The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 4,200,000 shares of common stock. The offering is expected to close on or about December 13, 2019, subject to customary closing conditions. 

Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

RADNOR, Pa., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by Marinus.  Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020

Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

100% of evaluable patients in target dose had no relapse during the four-week follow-up period

News for Marinus Pharmaceuticals Stock (MRNS)